SEC Filing Summary: Synta Pharmaceuticals Corp. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on January 7, 2014, covering events occurring on January 2 and January 3, 2014. The filing addresses executive leadership changes within the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Amar Singh resigned effective immediately on January 2, 2014, from his role as Senior Vice President and Chief Business Officer to pursue other opportunities.
- Appointment: Arthur McMahon was promoted on January 3, 2014, to the newly created position of Senior Vice President, People Operations.
- Role Realignment: Duties previously held by Mr. Singh are now split between Mr. McMahon and Steven Bernitz, who joined the company as Senior Vice President of Corporate Development on December 20, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on strategy, or specific risk factors beyond the operational impact of the executive departure.
Key Facts for Investor Verification
- Confirm the effective date of Amar Singh's resignation (January 2, 2014).
- Verify the new reporting structure for the Chief Business Officer duties between Arthur McMahon and Steven Bernitz.
- Check subsequent filings for any impact of this leadership change on the company's business development pipeline or strategic direction.